These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33342162)

  • 1. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
    Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy- A double Edged Sword; A case of Fatal Myocarditis and Complete Response.
    Peters N; Greally M; Breen K; Fabre A; Blazkova S
    Ir Med J; 2019 May; 112(5):937. PubMed ID: 31411390
    [No Abstract]   [Full Text] [Related]  

  • 3. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
    Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
    Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer.
    Tan JL; Mugwagwa AN; Cieslik L; Joshi R
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
    Callens R; Tamsin A; van Zandweghe L
    J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
    [No Abstract]   [Full Text] [Related]  

  • 6. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
    Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
    Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
    Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    Guaitoli G; Baldessari C; Tomasello C; Barbieri F; Cascinu S; Bertolini F; Cesinaro AM
    J Thorac Oncol; 2018 Aug; 13(8):e152-e153. PubMed ID: 30049380
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
    Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.
    Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
    Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
    Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
    Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature.
    Matsuo K; Ishiguro T; Najama T; Shimizu Y; Kobayashi Y; Mutou M
    Intern Med; 2019 Aug; 58(16):2367-2372. PubMed ID: 31118387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
    Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
    Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.